Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3013% below fair value
$2.01−0.06 (-2.66%)
Close on Nov 16, 2026Market cap $159.04MP/E 16.8Yield –
Niagen Bioscience EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Niagen Bioscience's EV/EBITDA was 9.3× on Nov 11, 2026, against 24.6× a year earlier. Over the last 2 years it ranged from 9.3× to 885.1×, with a median of 24.6×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 9.3× | −13.6 |
| 2025 | Dec 31, 2025 | 22.9× | −806.9 |
| 2024 | Dec 31, 2024 | 829.8× | – |
See a number that looks wrong?